Why Strong Science Isn’t Enough to Get Funded: What Investors Actually Look For – Part 2
Securing capital for biotech innovation has never been more challenging—or more crucial.
Why Strong Science Isn’t Enough to Get Funded: What Investors Actually Look For – Part 1
Strong science alone won’t get your biotech startup funded—investors are sizing up much more than just your molecule.
Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing – Part 2
What happens between scientific discovery and clinical trials?
Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing – Part 1
Picture the difference between a “drug” and a true “product”.
Is Bioprocess Education Keeping Up With New Tech? The Training Gap Industry Cannot Afford to Ignore – Part 2
What if the biggest advancement in bioprocessing isn’t a new AI algorithm or cutting-edge bioreactor, but a renewed focus on the foundational skills that drive innovation—and a clear-eyed look at what AI can (and can’t) really do for the industry right now?
Is Bioprocess Education Keeping Up With New Tech? The Training Gap Industry Cannot Afford to Ignore – Part 1
How do you bridge the gap between cutting-edge industrial bioprocessing and the academic world tasked with training the next generation?
How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers – Part 2
Can aging be fundamentally slowed or even reversed—not by science fiction, but by harnessing the unassuming power of super-early stem cells?
Nitrosamine Risk Assessment and CRO Selection: The $6 Million Mistake CMC Teams Must Avoid – Part 1
When drug safety fails, patients—and entire markets—pay the price. Understanding your CMC isn’t just compliance; it’s the line between therapeutic promise and product recall.
Why Your Shake Flask Culture Doesn’t Scale: OTR, Shaking Diameter, and How to Fix It – Part 2
What’s the real difference between a shake flask, a microtiter plate, and a full-scale bioreactor—and why do so many experiments go sideways, even when the SOP looks perfect?
Why Your Shake Flask Culture Doesn’t Scale: OTR, Shaking Diameter, and How to Fix It – Part 1
In bioprocess development, orbital-shaken bioreactors—shake flasks, spin tubes, and microtiter plates—are the unsung backbone powering industry decisions about production strains and media.